# Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

> **NCT02932280** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Solid Tumor
- Central Nervous System Tumor
- Lymphoma
- Leukemia

## Interventions

- **DRUG:** Neratinib

## Key facts

- **NCT ID:** NCT02932280
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02932280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02932280, "Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02932280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*